Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously and these cells are safe and effective for the treatment of severe SARS-CoV-2 infections.
Description: Dose-limiting toxicities are defined as >Grade 3 Common Toxicity Criteria associated with the therapeutic cells. Toxicity rate will be summarized descriptively.
Measure: Dose-Limiting Toxicities Time: till Day 28 after infusion of SARS-CoV-2 specific T cellsDescription: Measured by change in daily NEWS score after infusion of SARS-CoV-2 specific T cells
Measure: National Early Warning Score (NEWS) Time: one monthDescription: Measured by time-to-improvement by one category on a WHO ordinal scale after infusion of SARS-CoV-2 specific T cells
Measure: Time to improvement by one category on a WHO ordinal scale Time: one monthDescription: Measured by time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells
Measure: Time-to-SARS-CoV-2 negativity after infusion of SARS-CoV-2 specific T cells Time: two monthsDescription: Measured by the duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood
Measure: Duration of persistence of SARS-CoV-2 specific T cells in the recipient's blood circulation Time: two monthsDescription: Measured by the time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion
Measure: Time-to-normalization of cytokine level, lymphocyte subsets, and gene transcriptome after T cell infusion Time: two monthsDescription: Measured by the proportion of recipients surviving at 3 months after infusion of SARS-CoV-2 specific T cells
Measure: Overall survival (OS) at 3 months after infusion of SARS-CoV-2 specific T cells Time: three monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports